Technical Analysis for SNG - Synairgen Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 6.40 | -8.83% | -0.62 |
Earnings due: Apr 25
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Crossed Above 200 DMA | Bullish | -8.83% | |
| NR7 | Range Contraction | -8.83% | |
| Inside Day | Range Contraction | -8.83% | |
| Wide Bands | Range Expansion | -8.83% | |
| 200 DMA Resistance | Bearish | -5.19% | |
| Shooting Star Candlestick | Bearish | -5.19% | |
| Wide Bands | Range Expansion | -5.19% | |
| 200 DMA Resistance | Bearish | -5.19% | |
| Wide Bands | Range Expansion | -5.19% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 5 hours ago |
| Down 10% | about 8 hours ago |
| Fell Below Previous Day's Low | about 8 hours ago |
| 5x Volume Pace | about 8 hours ago |
| Outside Day | about 8 hours ago |
Free Daily (Stock) Chart Reading
Synairgen Plc Description
Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Bank Medicine Disease Clinic Diseases Biology Drug Discovery Therapy Respirator Beta Therapies Astrazeneca Respiratory Disease Respiratory Diseases Asthma Chronic Obstructive Pulmonary Disease Fibrosis In Vitro Respiratory Therapy Copd Idiopathic Pulmonary Fibrosis Pulmonology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.3 |
| 52 Week Low | 4.2 |
| Average Volume | 438,312 |
| 200-Day Moving Average | 6.82 |
| 50-Day Moving Average | 5.59 |
| 20-Day Moving Average | 6.07 |
| 10-Day Moving Average | 6.63 |
| Average True Range | 1.07 |
| RSI (14) | 53.92 |
| ADX | 37.62 |
| +DI | 24.84 |
| -DI | 10.54 |
| Chandelier Exit (Long, 3 ATRs) | 6.79 |
| Chandelier Exit (Short, 3 ATRs) | 7.41 |
| Upper Bollinger Bands | 7.73 |
| Lower Bollinger Band | 4.41 |
| Percent B (%b) | 0.6 |
| BandWidth | 54.71 |
| MACD Line | 0.36 |
| MACD Signal Line | 0.32 |
| MACD Histogram | 0.0365 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.20 | ||||
| Resistance 3 (R3) | 8.33 | 7.87 | 7.90 | ||
| Resistance 2 (R2) | 7.87 | 7.41 | 7.80 | 7.80 | |
| Resistance 1 (R1) | 7.13 | 7.13 | 6.90 | 7.00 | 7.70 |
| Pivot Point | 6.67 | 6.67 | 6.55 | 6.60 | 6.67 |
| Support 1 (S1) | 5.93 | 6.21 | 5.70 | 5.80 | 5.10 |
| Support 2 (S2) | 5.47 | 5.93 | 5.40 | 5.00 | |
| Support 3 (S3) | 4.73 | 5.47 | 4.90 | ||
| Support 4 (S4) | 4.60 |
